{
    "clinical_study": {
        "@rank": "110992", 
        "arm_group": [
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose of Rosuvastatin 20mg"
            }, 
            {
                "arm_group_label": "Fenofibric acid", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose of Fenofibric acid 135mg"
            }, 
            {
                "arm_group_label": "Rosuvastatin + Fenofibric acid", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics profile and drug-drug\n      interaction between rosuvastatin and fenofibric acid in healthy adult subjects"
        }, 
        "brief_title": "Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and Fenofibric Acid in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy adult male volunteers aged 19 to 45 years\n\n          2. A sybject who has judged to be healthy by the investigator to participate in this\n             study based on screening result\n\n          3. A subject who provided written informed consent to participate in this study and\n             cooperative with regared to compliance with study related constraints\n\n        Exclusion Criteria:\n\n          1. A subject with sign or symptoms or previously diagnosed disease of liver, digestive\n             system, cardiovascular, kidney, respiratory, endocrinology, neurology, immune system,\n             hematology, and psychology function or other significant disease and history.\n\n          2. A subject who shows the following result in clinical laboratory test\n\n               -  AST, ALT > 1.25 times of the upper limit of normal range\n\n               -  PR \u2265 210 msec\n\n               -  QRS \u2265 120 msec\n\n               -  QT \u2265 500 msec\n\n               -  QTcF \u2265 500 msec\n\n          3. Subject who has taken other clinical medication from another clinical trial within\n             60-day period prior to the first administration of the study medication"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964365", 
            "org_study_id": "DW_DWJ1330001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rosuvastatin", 
                "description": "tablet, rosuvastatin 20mg", 
                "intervention_name": "Cresto 20mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fenofibric acid", 
                "description": "capsule, fenofibric acid 135mg", 
                "intervention_name": "Fenofibric acid 135mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rosuvastatin + Fenofibric acid", 
                "description": "rosuvastatin 20mg, Fenofibric acid 135mg", 
                "intervention_name": "Cresto 20mg, Fenofibric acid 135mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fenofibric acid", 
                "Rosuvastatin", 
                "Fenofibrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Inje University College of Medicine Busan Paik Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Rosuvastatin and Fenofibric Acid in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "BUSAN PAIK HOSPITAL", 
            "last_name": "Jae-Gook Shin, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the periods"
            }, 
            {
                "measure": "AUCtau", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the periods"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964365"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmin", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the periods"
            }, 
            {
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the periods"
            }, 
            {
                "measure": "CL/F", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the periods"
            }, 
            {
                "measure": "T1/2", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the periods"
            }, 
            {
                "measure": "Metabolic Ratio", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the periods"
            }
        ], 
        "source": "Daewoong Pharmaceutical Co. LTD.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewoong Pharmaceutical Co. LTD.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}